Nasdaq-listed China Biologic raises $73.5M in follow-on offer

China Biologic Products raised $73.5 million by selling 700,000 shares at $105 each through follow-on offer by the Nasdaq-listed plasma-based biopharmaceutical company with primary operations in China. The company hired Morgan Stanley, Credit Suisse, Merrill Lynch, Jefferies and Lazard as underwriters. Release